Opthea Limited Net Income | OPT

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Opthea Limited

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-163 M	-220 M	-143 M	-92.8 M	-45.3 M	-11.1 M	-20.9 M	-16.9 M	-6.19 M	-6.51 M	-5.31 M	-4 M	-4.75 M	-4.84 M	-10.3 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-4 M	-220 M	-50.3 M

Quarterly Net Income Opthea Limited

2025-Q2	2024-Q2	2023-Q2	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-163 M	-220 M	-143 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-143 M	-220 M	-175 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
ADC Therapeutics SA ADCT	-143 M	$ 1.31	6.5 %	$ 166 M	Schweiz
ADMA Biologics ADMA	147 M	$ 9.7	3.21 %	$ 2.31 B	USA
Adaptive Biotechnologies Corporation ADPT	-59.5 M	$ 27.89	0.3 %	$ 4.23 B	USA
Arcturus Therapeutics Holdings ARCT	-65.8 M	$ 13.3	1.06 %	$ 364 M	Israel
AbbVie ABBV	1.82 B	$ 265.08	0.02 %	$ 469 B	USA
Axsome Therapeutics AXSM	-183 M	$ 193.45	0.24 %	$ 9.62 B	USA
Aytu BioScience AYTU	-14.3 M	$ 2.28	2.24 %	$ 28.1 M	USA
Adagene ADAG	-17.6 M	$ 2.97	0.62 %	$ 175 M	China
Abeona Therapeutics ABEO	-71.2 M	$ 5.53	2.65 %	$ 293 M	USA
Adial Pharmaceuticals ADIL	-7.98 M	$ 4.04	0.24 %	$ 2.7 M	USA
Evelo Biosciences EVLO	-115 M	-	-14.46 %	$ 27.9 M	USA
BioMarin Pharmaceutical BMRN	349 M	$ 62.21	0.06 %	$ 11.9 B	USA
Arbutus Biopharma Corporation ABUS	-33.5 M	$ 4.85	0.2 %	$ 929 M	Canada
Can-Fite BioPharma Ltd. CANF	-9.83 M	$ 2.16	0.45 %	$ 3.56 M	Israel
Achieve Life Sciences ACHV	-54.6 M	$ 7.83	0.87 %	$ 341 M	USA
Catalyst Biosciences CBIO	9.88 M	$ 14.19	1.17 %	$ 1.27 B	USA
Amryt Pharma plc AMYT	1 M	-	-	$ 621 M	Britain
C4 Therapeutics CCCC	-105 M	$ 3.08	0.3 %	$ 255 M	USA
Codexis CDXS	-44 M	$ 1.38	0.72 %	$ 120 M	USA
Allakos ALLK	-116 M	-	-	$ 28.6 M	USA
Cerus Corporation CERS	-15.6 M	$ 2.6	4.3 %	$ 496 M	USA
Coherus BioSciences CHRS	168 M	$ 1.26	1.48 %	$ 148 M	USA
Celldex Therapeutics CLDX	-259 M	$ 31.12	0.28 %	$ 2.07 B	USA
CollPlant Biotechnologies Ltd. CLGN	-11.5 M	$ 4.04	4.94 %	$ 49.3 M	Israel
AbCellera Biologics ABCL	-146 M	$ 12.31	0.12 %	$ 3.68 B	Canada
Aclaris Therapeutics ACRS	-64.9 M	$ 5.26	2.69 %	$ 645 M	USA
Фармсинтез LIFE	-525 M	-	-	-	Russia
Clovis Oncology CLVS	-64.4 M	-	-7.23 %	$ 13 M	USA
Cocrystal Pharma COCP	-8.83 M	$ 1.19	1.26 %	$ 13.4 M	USA
Collegium Pharmaceutical COLL	63 M	$ 22.45	1.05 %	$ 711 M	USA
Corcept Therapeutics Incorporated CORT	99.7 M	$ 112.94	3.29 %	$ 11.7 B	USA
Crinetics Pharmaceuticals CRNX	-465 M	$ 84.95	0.13 %	$ 7.99 B	USA
Corbus Pharmaceuticals Holdings CRBP	-78.5 M	$ 7.74	0.19 %	$ 103 M	USA
Cardiff Oncology CRDF	-45.9 K	$ 1.31	0.74 %	$ 87.6 M	USA
Curis CRIS	-7.58 M	$ 0.95	0.98 %	$ 12.5 M	USA
CorMedix CRMD	163 M	$ 7.69	0.06 %	$ 554 K	USA
CRISPR Therapeutics AG CRSP	-582 M	$ 55.76	1.2 %	$ 5.01 B	Schweiz
Corvus Pharmaceuticals CRVS	-15.3 M	$ 12.54	8.21 %	$ 990 M	USA
Concert Pharmaceuticals CNCE	-80.1 M	-	-	$ 401 M	USA
Cue Biopharma CUE	-26.6 M	$ 31.71	2.62 %	$ 3 B	USA
CEL-SCI Corporation CVM	-25.4 M	$ 1.68	0.59 %	$ 13.5 M	USA
Cytokinetics, Incorporated CYTK	-785 M	$ 65.81	0.04 %	$ 7.9 M	USA
Axon Enterprise AXON	125 M	$ 450.61	1.61 %	$ 35.2 B	USA
Brickell Biotech BBI	-5.69 M	-	-5.38 %	$ 6.06 M	USA
DiaMedica Therapeutics DMAC	-32.8 M	$ 7.56	7.16 %	$ 355 M	USA
Denali Therapeutics DNLI	-513 M	$ 20.46	5.52 %	$ 3.53 B	USA
Precision BioSciences DTIL	-45.7 M	$ 6.36	10.62 %	$ 81.6 M	USA
Dyadic International DYAI	-7.36 M	$ 0.41	3.72 %	$ 14.8 M	USA
Editas Medicine EDIT	-160 M	$ 2.69	0.17 %	$ 239 M	USA
Edesa Biotech EDSA	-7.19 M	$ 3.97	1.46 %	$ 22.5 M	USA